SUPPLEMENTARY MATERIAL

Ruxolitinib Cream As-Needed Monotherapy Demonstrates Sustained Disease and Symptom Control in Patients with Mild to Moderate Atopic Dermatitis: Pooled Analysis from Two Phase 3 Studies

Andrew Blauvelt, MD, MBA,[1,2] Leon Kircik, MD,[3,4] Eric L. Simpson, MD, MCR,[5] Peter Lio, MD,[6] Lawrence F. Eichenfield, MD,[7] Vimal H. Prajapati, MD,[8-13] Parbeer Grewal, MD,[14] Charles Lynde, MD,[15,16] H. Chih-ho Hong, MD,[17,18] Daniel Sturm, PharmD,[19] Howard Kallender, PhD,[19] Haobo Ren, PhD,[19] Dilan Paranagama, PhD,[19] Grace K. W. Wong, PhD,[20] Bob Geng, MD[7]

[1]Oregon Medical Research Center, Portland, OR, USA; [2]Blauvelt Consulting, LLC, Annapolis, MD, USA; [3]Icahn School of Medicine at Mount Sinai, New York, NY, USA; [4]Indiana University School of Medicine, Indianapolis, IN, USA; [5]Oregon Health & Science University, Portland, OR, USA; [6]Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; [7]University of California San Diego, La Jolla, CA, USA; [8]Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada; [9]Section of Community Pediatric, Department of Pediatrics, University of Calgary, Calgary, AB, Canada; [10]Section of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, AB, Canada; [11]Dermatology Research Institute, Calgary, AB, Canada; [12]Skin Health & Wellness Centre, Calgary, AB, Canada; [13]Probity Medical Research, Calgary, AB, Canada; [14]Rejuvenation Medical, Edmonton, AB, Canada; [15]Lynde Institute for Dermatology, Markham, ON, Canada; [16]Probity Medical Research, Markham, ON, Canada; [17]Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada; [18]Probity Medical Research, Surrey, BC, Canada; [19]Incyte Corporation, Wilmington, DE, USA; [20]Incyte Biosciences Canada, Pointe-Claire, QC, Canada

Corresponding author: Bob Geng, MD
University of California San Diego
3030 Children's Way # 2
La Jolla, CA, USA. 92123.
Phone: 858-966-5961
Email: geng.bob@gmail.com

Supplementary Material Fig. S1. Percentage of Visits* With IGA 0/1 Among Patients Who Achieved or Did Not Achieve IGA-TS, EASI-75, or Itch NRS 0/1 at Week 8



* Included patients with ≥2 visits.
EASI-75, ≥75% improvement from baseline in Eczema Area and Severity Index; IGA, Investigator's Global Assessment; IGA-TS, IGA treatment success; LTS, long-term safety; NRS, numerical rating scale.

Supplementary Material Fig. S2. Percentage of Visits* With IGA 0/1 in the LTS Period According to the Number of Prior Lines of Therapy



* For patients with ≥2 visits.
IGA, Investigator's Global Assessment; LTS, long-term safety.

Supplementary Material Fig. S3. Percentage of Treatment-Free Days Between Study Visits for Patients Who Did or Did Not Achieve (A) IGA-TS, (B) EASI-75, or (C) Itch NRS 0/1 at Week 8



* Line corresponds to affected BSA in the last week of the stated range.
BSA, body surface area; EASI-75, ≥75% improvement from baseline in Eczema Area and Severity Index; IGA, Investigator's Global Assessment; IGA-TS, IGA treatment success; LTS, long-term safety; NRS, numerical rating scale.

Supplementary Material Fig. S4. Time Off Treatment by Baseline Disease Severity and Extent



* As median percentage of the entire long-term safety period; 244 total patients were included in this analysis.
BSA, body surface area; IGA, Investigator's Global Assessment.

Supplementary Material Fig. S5. Time Off Treatment by Number of Prior Lines of Therapy



* As median percentage of the entire long-term safety period.